Publication | Closed Access

High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer

First-line TherapyOncologyGastrointestinal OncologyMedicineColorectal CancerMetastatic Colorectal CancerPharmacotherapyCancer TreatmentPharmacologyRadiation Oncology